Immunomodulation of tumor microenvironments

By using DNA enzymes to regulate the immunosuppressive tumor cell microenvironment in cancer patients and combined with immune checkpoint regulators, the problems of poor effectiveness and serious side effects of existing cancer treatment methods are solved, and the treatment response rate and safety are improved.

CN118946288APending Publication Date: 2024-11-12D·D·金基恩 +2

Patent Information

Application Number
CN202280051550.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-05-21
Filing Date
2022-05-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing cancer treatment methods, especially immune checkpoint modulator monotherapy, are not effective for certain types of cancer and frequent immune-related adverse events, resulting in low treatment response rates and serious side effects.

Method used

Deoxyribonuclease (DNase) is used to regulate the immunosuppressive tumor cell microenvironment in cancer patients, reduce the number and activity of tumor-associated macrophages and neutrophils, and combine immune checkpoint regulators to improve therapeutic effect. Reduce the severity of adverse events.

Benefits of technology

It effectively increases the killing ability of CD8 T cells and NK cells to tumor cells, improves the response rate of immune checkpoint therapy, reduces the severity of immune-related adverse events, and improves the effectiveness of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946288A_ABST
    Figure CN118946288A_ABST
Patent Text Reader

Abstract

The present invention relates to a method of immunomodulating an immunosuppressive tumor cell microenvironment and preventing tumor microbiome effects by various pathways using DNase therapy. Methods of immunomodulating an immunosuppressive tumor cell microenvironment include administering an effective amount of a deoxyribonuclease (DNase), alone or in combination with other immunomodulators.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 191,551, filed on May 21, 2021, the disclosure of which is incorporated herein by reference in its entirety.

[0003] Sequence Listing

[0004] This application includes a sequence listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy created on May 19, 2022 is named 252732_000038_SL.txt and is 14,097 bytes in size. Field of the Invention

[0005] The present invention relates to novel methods for immunomodulating the immunosuppressive tumor cell microenvironment and preventing tumor microbiome effects in patients with different cancers using deoxyribonucleases (DNases). Background of the Invention

[0007] Patients with malignancies have elevated levels of circulating cell-free DNA (cfDNA) in their plasma and serum compared to healthy individuals (Fleischhacker, 2007). In cancer patients, circulating cfDNA originates from dying non-tumor cells, tumor cells, and neutrophils. Tumors predispose neutrophils to release extracellular DNA traps (NETs), which promote the establishment of a prothrombotic state, cachexia, and organ failure in cancer patients (Demmers, 2012). Tumor-derived cfDNA can promote the development of metastasis and chemoresistance (García-Olmo, 2013). The amount of circulating cfDNA increases with tumor progression (Sawyers, 2008), reaching maximum levels in patients with advanced disease and metastatic disease (Butt, 2008). It has been shown that higher amounts of circulating cfDNA are significantly associated with poor patient survival (Schwarzenbach, 2008).

[0008] The inventors have previously demonstrated that systemic administration of high doses of DNase protein into the patient's circulation can be used to treat many diseases and conditions associated with elevated levels of cfDNA in the blood, including cancer (e.g., carcinoma, sarcoma, lymphoma, melanoma; see, e.g., U.S. Patent Nos. 7,612,032; 8,710,012; 9,248,166), the development of somatic chimerism (see, e.g., U.S. Patent Application Publication No. US20170056482), and side effects associated with chemotherapy or radiotherapy (see, e.g., U.S. Patent Application Publication No. US20170100463). All of these patents and applications are incorporated herein by reference in their entirety. Others have since demonstrated similar effects. (Wen, 2013; Cederval, 2015; Tohme, 2016; Patutina, 2011; Li, 2015).

[0009] Immune checkpoint inhibitors (ICIs) are currently approved for use in many cancers. However, reported objective response rates for monotherapy range between 28%-52% (Darvin et al., 2018). SUMMARY OF THE INVENTION

[0011] The present invention addresses a significant need in the art for new and more effective cancer treatments, particularly those cancers that cannot be effectively treated with immune checkpoint modulator monotherapy.

[0012] In one aspect, the present invention provides a method for immunomodulating an immunosuppressive tumor cell microenvironment in a subject having cancer, the method comprising administering to the subject an effective amount of deoxyribonuclease (DNase). In some embodiments, immunomodulation comprises increased killing of tumor cells by cytotoxic CD8 T cells and / or NK cells and / or CAR-T cells within the immunosuppressive tumor cell microenvironment.

[0013] In another aspect, the present invention provides a method of modulating a tumor-associated microbiome in a subject having cancer, the method comprising administering to the subject an effective amount of a deoxyribonuclease (DNase).

[0014] In an additional aspect, the invention provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a deoxyribonuclease (DNase) and a second immunomodulatory agent.

[0015] In some embodiments of any of the above methods, administering the DNase is effective to reduce the number and / or activity of tumor-associated macrophages (TAMs) and / or tumor-infiltrating neutrophils (TINs) in the immunosuppressive tumor cell microenvironment.

[0016] In some embodiments of the above-mentioned method involving the administration of a second immunomodulator, the second immunomodulator is an immune checkpoint regulator. In some embodiments, the immune checkpoint regulator is a regulator selected from the following immune checkpoint molecules: PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligand. In some embodiments, the immune checkpoint regulator is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1, or PD-L2. In some embodiments, the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA, or SIGLEC7. In some embodiments, the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cemiplimab, and any combination thereof. In some embodiments, the immune checkpoint inhibitor is pembrolizumab.

[0017] In some embodiments of any of the above methods of the present invention, the DNA enzyme is selected from human DNA enzyme I, human DNA enzyme-1-like 3 (D1L3), human DNA enzyme-1-like 2 (D1L2), human DNA enzyme-1-like 1 (D1L1), DNA enzyme X, DNA enzyme γ, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ and caspase activated DNA enzyme (CAD). In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with a human DNA enzyme I enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with SEQ ID NO:1. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of a DNA enzyme 1-like 3 (D1L3) enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:3. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:3. In some embodiments, the DNA enzyme comprises an amino acid sequence SEQ ID NO:2.

[0018] In some embodiments of any of the above methods of the present invention, DNA enzyme is administered as DNA enzyme protein. In some embodiments, DNA enzyme protein is administered intravenously for at least 2 days. In some embodiments, DNA enzyme protein is administered intravenously for at least 7 days. In some embodiments, DNA enzyme protein is administered intravenously for at least 14 days. In some embodiments, DNA enzyme protein is administered intravenously for at least 16 days. In some embodiments, DNA enzyme protein is administered intravenously for 1 day to 2 days every 2 weeks, 3 weeks or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years. In some embodiments, DNA enzyme protein is administered intravenously for 2 days to 5 days every 2 weeks, 3 weeks or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years. In some embodiments, DNA enzyme protein is administered intravenously for 7 days to 14 days every 2 weeks, 3 weeks or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years. In some embodiments, DNA enzyme protein is administered intravenously for 7 days to 14 days every 2 weeks, 3 weeks or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years. In some embodiments, DNA enzyme protein is administered with 125 μg / kg / day-250 μg / kg / day.

[0019] In some embodiments of any method related to the use of the second immunomodulator, the DNA enzyme protein is applied 120 hours to 1 hour before the second immunomodulator is applied. In some embodiments, the DNA enzyme protein is applied 30 minutes to 2 hours after the second immunomodulator is applied. In some embodiments, the DNA enzyme protein is applied 2 hours to 360 hours after the second immunomodulator is applied.

[0020] In some embodiments of any of the above methods of the present invention, the DNA enzyme is encoded by a gene therapy vector. In some embodiments, the gene therapy vector is administered to a subject. In some embodiments, the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector, comprising (i) capsid protein and (ii) nucleic acid, the nucleic acid comprising a promoter operably connected to a nucleotide sequence encoding the DNA enzyme. In some embodiments, the promoter is selected from a liver-specific promoter, a nervous system-specific promoter, an intestinal-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestinal-specific tandem promoter. In some embodiments, the promoter is specific for tumor-origin tissue or metastatic target tissue. In some embodiments, the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1 and Anc 80.

[0021] In some embodiments of any of the above methods of the present invention, DNA enzymes are expressed by cells comprising chimeric antigen receptors (CAR) or T cell receptors (TCR), and wherein the cells are administered to a subject. In some embodiments, CAR expressing cells or TCR expressing cells are directly administered to the tumor site. In some embodiments, CAR expressing cells or TCR expressing cells are single-target or multi-target. In some embodiments, CAR comprises an antigen binding domain that can specifically bind to one or more tumor antigens.

[0022] In some embodiments of any of the above methods of the invention involving the use of a second immunomodulator, administration of a DNA enzyme effectively reduces the severity of one or more immune-related adverse events associated with the use of the second immunomodulator. In some embodiments, such immune-related adverse events are cytokine release syndrome (CRS). In some embodiments, one or more immune-related adverse events are selected from uveitis, syndrome, conjunctivitis, blepharitis, episcleritis, scleritis, retinitis, pneumonia, pleurisy, sarcoid granulomatosis, hepatitis, pancreatitis, autoimmune diabetes, interstitial nephritis, glomerulonephritis, acute kidney injury (AKI), rash, pruritus, vitiligo, DRESS, psoriasis, Stevens-Johnson syndrome, arthralgia, arthritis, myositis, dermatomyositis, anemia, neutropenia, thrombocytopenia, thrombotic microangiopathy, acquired hemophilia, vasculitis, colitis, enteritis, gastritis, myocarditis, pericarditis, hypophysitis, thyroiditis, adrenalitis, encephalitis, meningitis, polyneuropathy, Guillain-Barré syndrome, and subacute inflammatory neuropathy.

[0023] In some embodiments of any of the above methods of the present invention, the administration of DNase results in changes in the content and / or activity of the tumor microbiome in the subject. In some embodiments, the tumor microbiome includes one or more bacterial taxa selected from the following: Acidobacteria, Actinobacteria, Bacteroidetes, Chlamydiae, Chrysiogenetes, Cyanobacteria, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Proteobacteria, Spirochaetes, Synergistetes, Tenericutes, and Verrucomicrobia.

[0024] In some embodiments of any of the above methods of the present invention, DNA enzyme is administered before, together with or after cell therapy.In some embodiments, cell therapy includes administering (i) cells comprising chimeric antigen receptor (CAR) or T cell receptor (TCR), and / or (ii) NK cells, and / or (iii) CD8 T cells.

[0025] In some embodiments of any of the aforementioned methods of the invention, the subject is a human.

[0026] In another aspect, the present invention provides a pharmaceutical composition comprising deoxyribonuclease (DNase), a second immunomodulator and a pharmaceutically acceptable carrier or excipient.

[0027] In a related aspect, the invention provides a pharmaceutical dosage form comprising a deoxyribonuclease (DNase) and a second immunomodulatory agent.

[0028] In a further aspect, the invention provides a kit comprising a deoxyribonuclease (DNase), a second immunomodulatory agent, and optionally instructions for use.

[0029] In some embodiments of any of the above-mentioned pharmaceutical compositions, dosage forms and kits, the second immunomodulator is an immune checkpoint regulator. In some embodiments, the immune checkpoint regulator is a regulator selected from the following immune checkpoint molecules: PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligand. In some embodiments, the immune checkpoint regulator is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1, or PD-L2. In some embodiments, the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA, or SIGLEC7. In some embodiments, the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cimiprilimumab, and any combination thereof. In some embodiments, the immune checkpoint inhibitor is pembrolizumab.

[0030] In some embodiments of any of the above pharmaceutical compositions, dosage forms and kits, the DNA enzyme is selected from human DNA enzyme I, human DNA enzyme-1-like 3 (D1L3), human DNA enzyme-1-like 2 (D1L2), human DNA enzyme-1-like 1 (D1L1), DNA enzyme X, DNA enzyme γ, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ and caspase activated DNA enzyme (CAD). In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with a human DNA enzyme I enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with SEQ ID NO:1. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of a DNA enzyme 1-like 3 (D1L3) enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:3. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:3. In some embodiments, the DNA enzyme comprises an amino acid sequence SEQ ID NO:2.

[0031] In some embodiments of any of the foregoing pharmaceutical compositions, dosage forms, and kits, the DNase is present in the form of a DNase protein.

[0032] In some embodiments of any of the above-mentioned pharmaceutical compositions, dosage forms and kits, the DNA enzyme is present in the form of a gene therapy vector encoding the DNA enzyme. In some embodiments, the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector, comprising (i) capsid protein and (ii) nucleic acid, the nucleic acid comprising a promoter operably connected to a nucleotide sequence encoding the DNA enzyme. In some embodiments, the promoter is selected from a liver-specific promoter, a nervous system-specific promoter, an intestinal-specific promoter, a liver-specific / nervous system-specific tandem promoter and a liver-specific / intestinal-specific tandem promoter. In some embodiments, the promoter is specific for tumor-origin tissue or metastatic target tissue. In some embodiments, the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1 and Anc 80.

[0033] In some embodiments of any of the above-mentioned pharmaceutical compositions, dosage forms and kits, the DNA enzyme is present in the form of a cell expressing the DNA enzyme and also comprising a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In some embodiments, CAR expressing cells or TCR expressing cells are single-target or multi-target. In some embodiments, CAR comprises an antigen binding domain that can specifically bind to one or more tumor antigens.

[0034] These and other aspects described herein will be apparent to those of ordinary skill in the art from the following description, claims and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Effect of DNA enzymes on (A) TAMs and (B) TINs in models of breast adenocarcinoma (MA), colorectal cancer (CRC), lung cancer (LC), and pancreatic adenocarcinoma (PDAC). In each experiment, the amount of TAMs and TINs was normalized to the percentage compared to the average TAMs and TINs in the PBS group (control, set to 100% CD45 in the tumor).

[0037] Figure 2 Effects of different treatment regimens of DNase administration on (A) TAMs and (B) TINs. In each experiment, the amounts of TAMs and TINs were normalized as percentages compared to the mean TAMs and TINs in the PBS group (control, set as 100% CD45 in tumors).

[0038] Figure 3 Effect of DNase administration on (A) TAMs and (B) TINs at different time periods after tumor implantation. In each experiment, the amount of TAMs and TINs was normalized as a percentage compared to the mean TAMs and TINs in the PBS group (control, set as 100% CD45 in tumors).

[0039] Figure 4 Effect of DNase administration in combination with checkpoint inhibitors on TAMs at different time periods after tumor implantation. In each experiment, the amount of TAMs was normalized as a percentage compared to the mean TAMs in the PBS group (control, set to 100% CD45 in tumors).

[0040] Figure 5 Role of DNA enzymes in regulating the pro-tumorigenic effects of the tumor microbiome. In each experiment, tumor size was normalized as a percentage compared to the mean size in Group 1 (control, set to 100%).

[0041] Figure 6DNase prevents inhibition of checkpoint inhibitor activity by the tumor microenvironment. In each experiment, tumor size was normalized as a percentage compared to the mean size in Group 1 (control, set to 100%).

[0042] Figure 7 DNA enzymes prevent toxicity associated with checkpoint inhibitor therapy. The figure shows the body weight after administration of the test items to C57BL / 6 mice bearing AT3 tumors. The data points represent the group average body weight. The error bars represent the standard error of the mean (SEM). Administration of anti-CTLA4 antibodies and Fusobacterium nucleatum (F.nucleatum) prevented weight gain in treated animals. The combination of CTLA4 antibodies and Fusobacterium nucleatum resulted in a strong weight loss. DNA enzyme I treatment prevented anti-CTLA4 and / or Fusobacterium nucleatum-induced toxicity and rescued weight gain. DETAILED DESCRIPTION OF THE INVENTION

[0044] The present invention is based on the inventors' hypothesis that targeting neutrophil extracellular traps (NETs), an extracellular network of DNA and proteins excreted by neutrophils into the tumor microenvironment, can improve the response rate to immune checkpoint therapy. Specifically, the inventors decided to combine immune checkpoint therapy with treatment with DNase, a NET depleting agent.

[0045] definition

[0046] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0047] Unless the context clearly dictates otherwise, the singular forms "a," "an," and "the" include plural referents. Thus, for example, reference to "a method" includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those skilled in the art upon reading this disclosure.

[0048] The term "about" or "approximately" includes within a range of statistically significant values. Such a range may be within a certain order of magnitude of a given value or range, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5%. The allowed variation encompassed by the term "about" or "approximately" depends on the specific system under study and can be readily understood by those of ordinary skill in the art.

[0049] The term “immunosuppressive tumor cell microenvironment” refers to noncancerous resident and infiltrating host cells, secreted factors, and extracellular matrix proteins within tumor tissue that together prevent tumor cell killing by cytotoxic CD8 T cells, NK cells, and / or CAR-T cells.

[0050] The term “tumor-associated microbiome” refers to microorganisms, their subcellular fractions, and their metabolites that reside within tumors.

[0051] The terms "extracellular DNA," "cell-free DNA," and "cfDNA" are used interchangeably to refer to extracellular DNA (e.g., DNA of eukaryotic, viral, archaeal, prokaryotic intracellular or extracellular parasitic origin), including DNA in extracellular vesicles (e.g., exosomes and microvesicles) found in any body fluids and tissues. cfDNA can be found in blood, lymph, liver, neural tissue, cerebrospinal fluid (CSF), and / or intestine, including DNA in extracellular vesicles (e.g., exosomes and microvesicles) found in these body fluids and tissues.

[0052] The term "treat" or "treatment" of a state, disorder or condition includes: (1) preventing, delaying or reducing the incidence and / or likelihood of development of at least one clinical or subclinical symptom of a state, disorder or condition in a subject who may be suffering from or susceptible to the state, disorder or condition but does not yet experience or show clinical or subclinical symptoms of the state, disorder or condition; or (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof or at least one clinical or subclinical symptom thereof; or (3) ameliorating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms. The benefit to the subject being treated is statistically significant or at least perceptible to the patient or to the physician.

[0053] The terms "individual," "subject," "animal," "patient," and "mammal" are used interchangeably to refer to mammals, including humans, veterinary animals (e.g., cats, dogs, cows, horses, sheep, pigs, etc.), and experimental animal models of disease (e.g., mice, rats).

[0054] The term "effective" as applied to dosage or amount refers to an amount of a compound or pharmaceutical composition sufficient to produce the desired activity upon administration to a subject in need thereof. Note that when a combination of active ingredients is administered, the effective amount of the combination may or may not include the amount of each ingredient that would be effective if administered alone. The exact amount required will vary between subjects depending on the species, age and general condition of the subject, the severity of the condition being treated, the specific drug or drugs used, the mode of administration, and the like.

[0055] As used herein, the term "therapeutically effective" as applied to a dose or amount refers to an amount of a compound or pharmaceutical composition sufficient to produce a desired activity after administration to a subject in need thereof. Note that when a combination of active ingredients (e.g., a combination of a DNA enzyme and another compound) is administered, the effective amount of the combination may or may not include the amount of each ingredient that would be effective if administered alone.

[0056] As used herein, the term "promoter" refers to a nucleic acid fragment whose function is to control the transcription of one or more coding sequences and is located upstream of the transcription start site of the coding sequence in the direction of transcription and is structurally identified by the presence of a binding site for a DNA-dependent RNA polymerase, a transcription start site, and any other DNA sequence, including but not limited to a transcription factor binding site, a repressor protein and an activator protein binding site, and any other nucleotide sequence known to those skilled in the art that is directly or indirectly used to regulate the amount of transcription of the promoter. A "tissue-specific" promoter may be preferentially active in a specific type of tissue or cell.

[0057] As used herein, the term "liver-specific expression" refers to expression predominantly or exclusively in the liver, ie, expression to a much greater extent than in other tissues and organs.

[0058] The term "liver-specific promoter" is used herein to refer to a promoter that is primarily or exclusively active in liver cells (liver cells) (e.g., hepatocytes), and directs / starts transcription in the liver to a much greater extent than in other tissues and organs. In this case, the term "primarily" means that at least 50% of the expression driven by the promoter, more typically at least 90% of the expression driven by the promoter (such as 100% of the expression driven by the promoter) occurs in liver cells. The ratio of liver expression to non-liver expression may be different between different liver-specific promoters. In some embodiments, a liver-specific promoter may preferentially direct / start transcription in a specific liver cell type (e.g., hepatocytes, Kupffer cells, endothelial cells, etc.). Some liver-specific promoters useful in the expression cassette of the present invention include at least one, usually several, liver nuclear factor binding sites. Liver-specific promoters useful in the expression cassette of the present invention may be constitutive or inducible promoters. Some non-limiting examples of liver promoters useful in the expression cassettes of the present invention include: albumin promoter (Alb), human alpha-1 antitrypsin (hAAT) promoter, thyroxine binding globulin (TBG), apolipoprotein E liver control region promoter, apolipoprotein A-II (APOA2) promoter, serine protease inhibitor peptidase inhibitor branch A member 1 (SERPINA1) (hAAT) promoter, cytochrome P450 family 3 subfamily A polypeptide 4 (CYP3A4) promoter, microRNA122 (miR-122) promoter, liver-specific IGF-II promoter P1, murine thyroxine transporter (MTTR) promoter, alpha-fetoprotein (AFP) promoter, lecithin cholesterol acyltransferase (LCAT) promoter, apolipoprotein H (ApoH) promoter, and mouse prealbumin gene promoter.

[0059] Non-limiting examples of liver-specific promoters include, for example, albumin promoter (Alb), human alpha-1 antitrypsin (hAAT) promoter, thyroxine binding globulin (TBG) promoter, apolipoprotein E liver control region promoter, apolipoprotein A-II (APOA2) promoter, serine protease inhibitor peptidase inhibitor branch A member 1 (SERPINA1) (hAAT) promoter, cytochrome P450 family 3 subfamily A polypeptide 4 (CYP3A4) promoter, microRNA122 (miR-122) promoter, liver-specific IGF-II promoter P1, mouse thyroxine transporter (MTTR) promoter, alpha-fetoprotein (AFP) promoter, thyroid hormone binding globulin promoter, alcohol dehydrogenase promoter, factor VIII (FVIII) promoter, HBV basic core promoter (BCP) and PreS2 promoter, Phosphoenolpyruvate carboxykinase (PEPCK) promoter, hepatic control region (HCR)-ApoCII hybrid promoter, AAT promoter combined with mouse albumin gene enhancer (Ealb) element, low-density lipoprotein promoter, pyruvate kinase promoter, phosphoenolpyruvate carboxykinase promoter, lecithin cholesterol acyltransferase (LCAT) promoter, apolipoprotein H (ApoH) promoter, transferrin promoter, thyroxine transporter promoter, α-fibrinogen and β-fibrinogen promoters, α1-antichymotrypsin promoter, α2-HS glycoprotein promoter, haptoglobin promoter, ceruloplasmin promoter, plasminogen promoter, complement protein (e.g., C1q, C1r, C2, C3, C4, C5, C6, C8, C9, complement factor I and factor H) promoter, C3 complement activator and [α]1-acid glycoprotein promoter. Additional tissue-specific promoters can be found in the Tissue-Specific Promoter Database (TiProD) (Nucleic Acids Research, J4: D104-D107 (2006)).

[0060] The term "nervous system specific promoter" is used herein to refer to such a promoter: mainly or exclusively active in nervous system cells, and in the nervous system (e.g., central nervous system (CNS), including brain and / or enteric nervous system (ENS)) instructs / starts transcription to a much greater extent than in other tissues and organs. In this case, the term "mainly" means that at least 50% of the expression driven by the promoter, more typically at least 90% of the expression driven by the promoter (such as 100% of the expression driven by the promoter) occurs in cells of the nervous system. The ratio of nervous system expression to non-nervous system expression can be different between different nervous system specific promoters. In some embodiments, a nervous system specific promoter can preferentially guide / start transcription in specific CNS and / or ENS cell types (e.g., neurons, glial cells [e.g., oligodendrocytes, astrocytes, ependymal cells, microglia, Schwann cells (Schwann cell), satellite cells], enteric neurons, intrinsic primary afferent neurons, interneurons, motor neurons, etc.). The nervous system specific promoter useful in the expression cassette of the present invention can be a constitutive or inducible promoter. Some non-limiting examples of nervous system promoters useful in the expression cassette of the present invention include microglia specific promoters (e.g., F4 / 80, CD68, TMEM119, CX3CR1, CMV and Iba1 promoters), myeloid cell specific promoters (e.g., TTR, CD11b and c-fes promoters), neuron specific promoters (e.g., CMV, NSE, synaptic protein [SynI, SynII], CamKII, α-CaMKII and VGLUT1 promoters) and other neural cells and glial cells (e.g., oligodendrocytes, astrocytes) type specific promoters (e.g., glial fibrillary acid protein [GFAP] promoter).

[0061] The term "intestinal-specific promoter" is used herein to refer to a promoter that is primarily or exclusively active in intestinal cells and directs / initiates transcription to a much greater extent in the intestine than in other tissues and organs. In this case, the term "primarily" means that at least 50% of the expression driven by the promoter, more typically at least 90% of the expression driven by the promoter (such as 100% of the expression driven by the promoter) occurs in intestinal cells. The ratio of intestinal expression to non-intestinal expression may vary between different intestinal-specific promoters. In some embodiments, an intestinal-specific promoter may preferentially direct / initiate transcription in a specific intestinal cell type (e.g., intestinal cells, goblet cells, enteroendocrine cells, etc.). Intestinal-specific promoters useful in the expression cassette of the present invention may be constitutive or inducible promoters. Some non-limiting examples of intestinal promoters useful in the expression cassette of the present invention include CB / CMV, GFAP, miCMV, CMV+I, tetO-CMV, β-acti-CMV, MUC2, villin, and T3 b Promoter.

[0062] In some embodiments, for example, when tissue targeting is mediated by viral capsid proteins, the nucleic acid encoding the DNase can be operably linked to a promoter that allows efficient systemic expression (e.g., CMV promoter, chicken β-actin promoter (CBA), or EF1a promoter).

[0063] The phrase "pharmaceutically acceptable" as used in conjunction with the compositions of the present invention refers to the molecular entities and other ingredients of such compositions that are physiologically tolerable and do not generally produce adverse reactions when administered to a subject (e.g., a mammal such as a human). As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.

[0064] As used herein, the terms "viral vector" and "viral construct" refer to a recombinant viral construct comprising one or more heterologous nucleotide sequences (e.g., a nucleotide sequence encoding a DNA enzyme). In some embodiments, the viral vector is replication-deficient. In some embodiments, viral structural coding sequences and non-structural coding sequences are not present in the viral vector, and are provided in trans by a vector such as a plasmid during viral vector production, or by stably integrating the sequence into a packaging cell line. Depending on the virus, the viral vector can be packaged in a capsid (e.g., an AAV vector) and / or a lipid envelope (e.g., a lentiviral vector).

[0065] In accordance with the present invention, conventional pharmacology and molecular biology techniques within the skill of the art may be employed. Such techniques are fully explained in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, 2nd Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (referred to herein as "Sambrook et al., 1989"); DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover, ed., 1985); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Nucleic Acid Hybridization (B. D. Hames and S. J. Higgins, eds. (1985)); Transcription and Translation (B. D. Hames and S. J. Higgins, eds. (1984)); Animal Cell Culture (R. I. Freshney, ed. (1986); Immobilized Cells and Enzymes (I. R. L. Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning: A Laboratory Manual, 2nd Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Cloning (1984); FM Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994); and others.

[0066] Method of the present invention

[0067] In one aspect, the present invention provides a method for immunomodulating the tumor microenvironment and / or preventing the effects of the tumor microbiome in a subject in need thereof, the method comprising administering deoxyribonuclease (DNA enzyme) to the subject. In another aspect, the present invention provides a method for reducing the intensity of adverse events via immunomodulating the tumor microenvironment and preventing the effects of the tumor microbiome, the adverse events including immune-related adverse events of immune checkpoint regulator therapy.

[0068] In one aspect, the invention provides a method of immunomodulating an immunosuppressive tumor cell microenvironment in a subject having cancer, the method comprising administering to the subject an effective amount of a DNase.

[0069] In another aspect, the present invention provides a method of modulating a tumor-associated microbiome in a subject having cancer, the method comprising administering to the subject an effective amount of a DNase.

[0070] In another aspect, the present invention provides a method for treating cancer in a subject in need thereof, the method comprising administering an effective amount of DNA enzyme and a second immunomodulator to the subject. In some embodiments, the second immunomodulator is an immune checkpoint regulator. In some embodiments, the immune checkpoint regulator is a regulator selected from the following immune checkpoint molecules: PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligand. In some embodiments, the immune checkpoint regulator is an immune checkpoint inhibitor. Non-limiting examples of useful immune checkpoint inhibitors include, for example, antibodies that specifically bind to CTLA-4, PD-1, PD-L1, PD-L2, OX-40, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA, or SIGLEC7. In some embodiments, the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cimiprilimumab, and any combination thereof. In some embodiments, administration of DNA enzymes effectively reduces the severity of one or more immune-related adverse events associated with the use of a second immunomodulator. In some embodiments, immune-related adverse events are cytokine release syndrome (CRS). Other non-limiting examples of immune-related adverse events include, for example, uveitis, syndrome, conjunctivitis, blepharitis, episcleritis, scleritis, retinitis, pneumonia, pleurisy, sarcoid granulomatosis, hepatitis, pancreatitis, autoimmune diabetes, interstitial nephritis, glomerulonephritis, acute kidney injury (AKI), rash, pruritus, vitiligo, DRESS, psoriasis, Stevens-Johnson syndrome, arthralgia, arthritis, myositis, dermatomyositis, anemia, neutropenia, thrombocytopenia, thrombotic microangiopathy, acquired hemophilia, vasculitis, colitis, enteritis, gastritis, myocarditis, pericarditis, hypophysitis, thyroiditis, adrenalitis, encephalitis, meningitis, polyneuropathy, Guillain-Barré syndrome, and subacute inflammatory neuropathy.

[0071] In some embodiments of any of the methods of the invention, administration of a DNA enzyme results in changes in the content and / or activity of a tumor microbiome in a subject. In some embodiments, the tumor microbiome includes one or more bacterial taxa selected from the following: Acidobacteria, Actinobacteria, Bacteroidetes, Chlamydiae, Chrysiogenetes, Cyanobacteria, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Proteobacteria, Spirochaetes, Synergistetes, Tenericutes, and Verrucomicrobia.

[0072] In one aspect, the present invention provides a method for immunomodulating a tumor microenvironment and preventing the effects of a tumor microbiome in a subject in need thereof, wherein the tumor microbiome is represented by bacteria, fungi, and viruses.

[0073] In one aspect, the present invention provides a method for reducing the intensity of adverse events, including immune-related adverse events of immune checkpoint modulator therapy, via immunomodulation of the tumor microenvironment and prevention of tumor microbiome effects.

[0074] In one aspect, the present invention provides a method for immunomodulating a tumor microenvironment and preventing a tumor microbiome effect in a subject in need thereof, wherein the bacteria of the tumor microbiome are from Acidobacteria, Actinobacteria, Bacteroidetes, Chlamydiae, Chrysiogenetes, Cyanobacteria, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Proteobacteria, Spirochaetes, Synergistetes, Tenericutes and / or Verrucomicrobia.

[0075] In one aspect, the present invention provides a method of immunomodulating a tumor microenvironment and preventing the effects of a tumor microbiome in a subject in need thereof, wherein the bacteria of the tumor microbiome represent Fusobacteriales, Enterobacterales and / or Bacillales.

[0076] In some embodiments of any of the above methods, administering the DNase is effective to reduce the number and / or activity of tumor-associated macrophages (TAMs) and / or tumor-infiltrating neutrophils (TINs) in the immunosuppressive tumor cell microenvironment.

[0077] In some embodiments of any of the above methods, the DNase is selected from DNase I, DNase X, DNase γ, DNase 1L1, DNase 1L2, DNase 1L3, DNase II, DNase IIα, DNase IIβ, caspase-activated DNase (CAD), endonuclease G (ENDOG), granzyme B (GZMB), and mutants or derivatives thereof.

[0078] In some embodiments of any of the above methods, the DNase is administered as a DNase protein. In some embodiments, the DNase protein is administered parenterally.

[0079] In some embodiments of any of the above methods, the DNase is DNase I or a mutant or derivative thereof.

[0080] In some embodiments, the DNA enzyme I mutant comprises one or more mutations in the actin binding site. In some embodiments, one or more mutations in the actin binding site are selected from mutations at Gln-9, Glu-13, Thr-14, His-44, Asp-53, Tyr-65, Val-66, Val-67, Glu-69, Asn-74, Ala-114, and any combination thereof. In some embodiments, one of the mutations in the actin binding site is a mutation at Ala-114. In some embodiments, the DNA enzyme I mutant comprises one or more mutations that increase DNA enzyme activity. In some embodiments, one or more mutations that increase DNA enzyme activity are selected from the group consisting of: Q9R, E13R, E13K, T14R, T14K, H44R, H44K, N74K, A114F, and any combination thereof. In some embodiments, the one or more mutations that increase DNase activity are selected from the group consisting of: Q9R, E13R, N74K, and A114F, and any combination thereof. In some embodiments, the DNase I mutant comprises mutations Q9R, E13R, N74K, and A114F. In some embodiments, the DNase I mutant comprises one or more mutations selected from the group consisting of: H44C, H44N, L45C, V48C, G49C, L52C, D53C, D53R, D53K, D53Y, D53A, N56C, D58S, D58T, Y65A, Y65E, Y65R, Y65C, V66N, V67E, V67K, V67C, E69R, E69C, A114C, A114R, H44 In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with a human DNA enzyme I. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of a DNA enzyme 1-like 3 (D1L3) enzyme (SEQ ID NO: 3).

[0081] In some embodiments of any of the above methods using DNA enzyme proteins, after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 14 days. In some embodiments, after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 16 days. In some embodiments, before the infusion of immune checkpoint regulators, together with the infusion of immune checkpoint regulators or after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 2 days. In some embodiments, before the infusion of immune checkpoint regulators or after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 1 day. In some embodiments, after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 7 days. In some embodiments, before the infusion of immune checkpoint regulators or after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins continues for at least 7 days. In some embodiments, before the infusion of immune checkpoint regulators or after the infusion of immune checkpoint regulators, the intravenous injection of DNA enzyme proteins every other day continues for at least 2 days. In some embodiments, before or after the infusion of immune checkpoint regulators, DNA enzyme protein is injected intravenously every other day for at least 5 days. In some embodiments, before or after the infusion of immune checkpoint regulators, DNA enzyme protein is injected intravenously every other day for at least 7 days. In some embodiments, before or after the infusion of immune checkpoint regulators, DNA enzyme protein is injected intravenously every other day for at least 14 days. In some embodiments, before or after the infusion of immune checkpoint regulators, DNA enzyme protein is injected intravenously every other day for 2 to 7 days. In some embodiments, DNA enzyme protein is injected intravenously every other day for a total of 2 to 7 days of intermittent process before or after the infusion of immune checkpoint regulators.

[0082] The administration of the DNA enzyme protein according to the method of the present invention can be carried out by any suitable approach, including systemic administration and direct administration to the disease site (e.g., administration to a primary tumor). The specific non-limiting examples of useful administration routes include intravenous (IV), subcutaneous (SC), intraperitoneal (IP), oral and intramuscular.

[0083] In certain embodiments, the DNase protein is formulated into a pharmaceutical composition containing a pharmaceutically acceptable carrier or excipient.

[0084] In some embodiments of any of the above methods, the DNA enzyme is encoded by a gene therapy vector. In some embodiments, the gene therapy vector is administered to a subject. In some embodiments, the gene therapy vector is a viral vector. Non-limiting examples of useful viral vectors include, for example, adeno-associated virus (AAV) vectors, adenoviral vectors, retroviral vectors (e.g., lentiviral vectors) and hepatotropic virus vectors (e.g., hepatitis B virus (HBV) vectors).

[0085] In some embodiments of any of the above methods using a gene therapy vector, the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding a DNase. Non-limiting examples of AAV serotypes that can be used to develop AAV expression vectors of the present invention include, for example, AAV serotype 1 (AAV1), AAV2, AAV3 (including type 3A and type 3B), AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAV-LK03, AAV-LK06, AAV-LK-01-19, AAV-LK12, AAV-KP1, AAVKP2-KP11, AAV-F, AAVrh64R1, AAVhu37, Anc80, Anc80L65, AAV-DJ, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and chimeras thereof. In some embodiments, the promoter is specific for a tumor tissue of origin or a metastasis target tissue. In some embodiments, the promoter is selected from a liver-specific promoter, a nervous system-specific promoter, an intestine-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestine-specific tandem promoter.

[0086] In some embodiments of any of the above methods, the DNA enzyme is expressed by a cell comprising a chimeric antigen receptor (CAR) or a T cell receptor (TCR), and the cell is administered to a subject. In some embodiments, the CAR-expressing cell or TCR-expressing cell is directly administered to the tumor site. In some embodiments, the CAR-expressing cell or TCR-expressing cell is single-target or multi-target. In some embodiments, CAR comprises an antigen binding domain capable of specifically binding to one or more tumor antigens. In some embodiments of any of the above methods, the CAR-expressing cell or TCR-expressing cell is further modified to express an immune checkpoint inhibitor molecule. In some embodiments, the CAR-expressing cell is a CAR T cell. In some embodiments, CAR comprises an antigen binding domain capable of specifically binding to one or more antigens selected from the following: (i) tumor antigens selected from CD5, CD7, CD19, CD28, mesothelin, CD123, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-β, SSEA-4, CD20, folate receptor α, FR-1, c-MET, EGFR / CD133, IL13Ra2, HER2, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostate enzymes, PAP, ELF2M, ephrin B2, IGF-I receptor, CAIX, LMP2 , gp100, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor β, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WTl, NY-ESO-1, LAGE-1a, MAGE-A1, legumin, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin, telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG(TMPRSS2 ETS fusion gene), NAI7, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYPIB1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase and muthsp70-2; (ii) antigens associated with solid tumors; (iii) solid tumor-associated antigens selected from mesothelin, EGFRvIII, GD2, CLDN6, Tn Ag, PSMA, CD97, TAG72, CD44v6, CEA, EPCAM, KIT, IL-13Ra2, legumin, CD171, PSCA, TARP, MAD-CT-1, Lewis Y, CD24, folate receptor alpha, folate receptor beta, ERBBs, MUC1, EGFR, NCAM, PDGFR-beta, MAD-CT-2, Fos-related antigen, SSEA-4, neutrophil elastase, CAIX, HPVE6 E7, ML-IAP, NA17, ALK, androgen receptor, polysialic acid, TRP-2, CYP1B 1, PLAC1, GloboH, NY-BR-1, sperm protein 17, HMWMAA, beta human chorionic gonadotropin, AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, intestinal carboxylesterase, and mut hsp 70-2; (iv) solid tumor associated antigens present in / on mesothelioma, lung cancer, pancreatic cancer, esophageal adenocarcinoma, ovarian cancer, breast cancer, colorectal cancer, bladder cancer, or any combination thereof; (v) tumor antigens associated with hematological cancers; (vi) tumor antigens present in a disease selected from the group consisting of: acute leukemias, including but not limited to B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), and acute lymphoblastic leukemia (ALL); or one or more chronic leukemias, including chronic myeloid leukemia (CIL) and chronic lymphocytic leukemia (CLL); and (vii) tumor antigens present in treatment-resistant cancers. ,

[0087] DNA enzyme

[0088] As used herein, the terms "deoxyribonuclease" and "DNA enzyme" are used to refer to any enzyme that catalyzes the hydrolytic cleavage of phosphodiester bonds in the DNA backbone. A variety of deoxyribonucleases are known and can be used in the methods of the present invention. Non-limiting examples of DNA enzymes useful in the methods of the present invention include, for example, DNA enzyme I (e.g., recombinant human DNA enzyme I (rhDNA enzyme I) or bovine pancreatic DNA enzyme I), analogs of DNA enzyme I (such as, for example, DNA enzyme X, DNA enzyme γ, DNA enzyme 1L1, DNA enzyme 1L2, DNA enzyme 1L3), DNA enzyme II (e.g., DNA enzyme IIα, DNA enzyme IIβ), caspase-activated DNA enzyme (CAD), endonuclease G (ENDOG), granzyme B (GZMB), phosphodiesterase I, lactoferrin, acetylcholinesterase and mutants or derivatives thereof. The present invention also encompasses DNA enzymes with extended half-lives (e.g., albumin and / or Fc fusion proteins, or protected from binding to actin by modifying the actin binding site; see, e.g., Gibson et al., (1992) J. Immunol. Methods, 155, 249-256). The actin binding site of DNA enzyme I can be mutated, for example, at the following residues: Gln-9, Glu-13, Thr-14, His-44, Asp-53, Tyr-65, Val-66, Val-67, Glu-69, Asn-74, Ala-114 of recombinant human DNA enzyme I (SEQ ID NO: 1). For example, a human DNA enzyme I hyperactive variant comprises a mutated Ala-114 residue. Other exemplary mutations include, for example, H44C, H44N, L45C, V48C, G49C, L52C, D53C, D53R, D53K, D53Y, D53A, N56C, D58S, D58T, Y65A, Y65E, Y65R, Y65C, V66N, V67E, V67K, V67C, E69R, E69C, A114C, H44N:T46S, D53R:Y66 5A, D53R:E69R, H44A:D53R:Y65A, H44A:Y65A:E69R, H64N:V66S, H64N:V66T, Y65N:V67S, Y65N:V67T, V66N:S68T, V67N:E69S, V67N:E69T, S68N:P70S, S68N:P70T, S94N:Y96S, S94N:Y96T (in the sequence of SEQ ID NO: 1). Mutations of DNase I with increased DNase I activity are also encompassed.Non-limiting examples of such mutations are, for example, Q9R, E13R, E13K, T14R, T14K, H44R, H44K, N74K and A114F of recombinant human DNase I (SEQ ID NO: 1). For example, a hyperactive DNase I mutant comprises a combination of Q9R, E13R, N74K and A114F mutations. DNase I preferentially cleaves DNA at the phosphodiester bond adjacent to pyrimidine nucleotides, generating a 5'-phosphate-terminated polynucleotide with a free hydroxyl group at the 3' position, generating an average of four nucleotides. DNase I acts on single-stranded DNA, double-stranded DNA and chromatin.

[0089] In some embodiments, the DNase may be DNase I or a mutant or derivative thereof.

[0090] In some embodiments, the DNase I may be human DNase I or a mutant or derivative thereof. In some embodiments, the DNase I may be non-human DNase I or a mutant or derivative thereof, such as, but not limited to, rodent (e.g., mouse) DNase I or a mutant or derivative thereof.

[0091] In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with human DNA enzyme I. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with human DNA enzyme I enzyme (SEQ ID NO: 1). In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with human DNA enzyme I enzyme mutant (SEQ ID NO: 2).

[0092] In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to amino acids 21 to 305 of a DNA enzyme 1-like 3 (D1L3) enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity to amino acids 21 to 305 of a human DNA enzyme 1-like 3 (D1L3) enzyme (SEQ ID NO: 3).

[0093] In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to amino acids 21 to 305 of a DNA enzyme 1-like 2 (D1L2) enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity to amino acids 21 to 305 of a human DNA enzyme 1-like 2 (D1L2) enzyme (SEQ ID NO: 4).

[0094] In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with amino acids 21 to 305 of a DNA enzyme 1-like 1 (D1L1) enzyme. In some embodiments, the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of a human DNA enzyme 1-like 1 (D1L1) enzyme (SEQ ID NO: 5).

[0095] In some embodiments, the DNA enzyme is a DNA enzyme I mutant comprising one or more mutations in the actin binding site. In some embodiments, the one or more mutations in the actin binding site are selected from mutations at Gln-9, Glu-13, Thr-14, His-44, Asp-53, Tyr-65, Val-66, Val-67, Glu-69, Asn-74, Ala-114, and any combination thereof. In some embodiments, one of the mutations in the actin binding site is a mutation at Ala-114.

[0096] In some embodiments, the DNA enzyme is a DNA enzyme I mutant comprising one or more mutations that increase the DNA enzyme activity. In some embodiments, the one or more mutations that increase the DNA enzyme activity are selected from the group consisting of: Q9R, E13R, E13K, T14R, T14K, H44R, H44K, N74K, A114F and any combination thereof. In some embodiments, the one or more mutations that increase the DNA enzyme activity are selected from the group consisting of: Q9R, E13R, N74K and A114F.

[0097] In some embodiments, the DNA enzyme is a DNA enzyme I mutant comprising one or more mutations selected from the group consisting of: H44C, H44N, L45C, V48C, G49C, L52C, D53C, D53R, D53K, D53Y, D53A, N56C, D58S, D58T, Y65A, Y65E, Y65R, Y65C, V66N, V67E, V67K, V67C, E69R, E69C, A114C, A114R, H44N:T46S, D53R:Y65A, D53R:E69R, H44A:D53R:Y65A, H44A:Y65A:E69R, H64N:V66S, H64N:V66T, Y65N:V67S, Y65N:V67T, V66N:S68T, V67N:E69S, V67N:E69T, S68N:P70S, S68N:P70T, S94N:Y96S, S94N:Y96T and any combination thereof. In some embodiments, the DNA enzyme I mutant is a long-acting form of DNA enzyme. In some embodiments, the DNA enzyme I mutant is a super active variant form of DNA enzyme. In some embodiments, the DNA enzyme I mutant comprises the amino acid sequence SEQ ID NO:2.

[0098] In some embodiments, the DNase I mutant comprises mutations Q9R, E13R, N74K, and A114F.

[0099] In some embodiments, the DNase I mutant comprises mutations Q9R, E13R, N74K, and A114F.

[0100] In some embodiments of any method of the present invention, the sequence encoding the DNA enzyme comprises a secretion signal sequence. In some embodiments, wherein the DNA enzyme is administered as a recombinant vector, the secretion signal sequence mediates the effective secretion of the enzyme into the portal sinus circulation when the vector is administered to the subject. In some embodiments, the secretion signal sequence is selected from the group consisting of: a DNA enzyme I secretion signal sequence, an IL2 secretion signal sequence, an albumin secretion signal sequence, a β-glucosidase secretion signal sequence, an alkaline protease secretion signal sequence, and a fibronectin secretion signal sequence. In some embodiments, the secretion signal sequence comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the sequence MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6). In some embodiments, the secretion signal sequence comprises the sequence MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6). In some embodiments, the secretion signal sequence consists of the sequence MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6). In some embodiments, the secretion signal sequence comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the sequence MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7). In some embodiments, the secretion signal sequence comprises the sequence MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7). In some embodiments, the secretion signal sequence consists of the sequence MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7).

[0101] In some embodiments, the DNA enzyme is selected from the group consisting of: DNA enzyme I, DNA enzyme X, DNA enzyme γ, DNA enzyme 1L1, DNA enzyme 1L2, DNA enzyme 1L3, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ, caspase activated DNA enzyme (CAD), endonuclease G (ENDOG), granzyme B (GZMB), phosphodiesterase I, lactoferrin, acetylcholinesterase and mutants or derivatives thereof. In some embodiments, the enzyme having DNA enzyme activity is DNA enzyme I or a mutant or derivative thereof. In some embodiments, DNA enzyme I is human DNA enzyme I or a mutant or derivative thereof. In some embodiments, the DNA enzyme I mutant comprises one or more mutations in the actin binding site. In some embodiments, one or more mutations in the actin binding site are selected from mutations at Gln-9, Glu-13, Thr-14, His-44, Asp-53, Tyr-65, Val-66, Val-67, Glu-69, Asn-74, Ala-114, and any combination thereof. In some embodiments, one of the mutations in the actin binding site is a mutation at Ala-114. In some embodiments, the DNase I mutant comprises one or more mutations that increase DNase activity. In some embodiments, one or more mutations that increase DNase activity are selected from the group consisting of: Q9R, E13R, E13K, T14R, T14K, H44R, H44K, N74K, A114F, and any combination thereof. In some embodiments, one or more mutations that increase DNase activity are selected from the group consisting of: Q9R, E13R, N74K, and A114F, and any combination thereof. In some embodiments, the DNA enzyme I mutant comprises a sequence having at least 80% or at least 85% or at least 90% or at least 95% sequence identity to the sequence of SEQ ID NO: 2. In some embodiments, the DNA enzyme I mutant comprises mutations Q9R, E13R, N74K and A114F. In some embodiments, the DNA enzyme I mutant comprises the sequence of SEQ ID NO: 2. In some embodiments, the DNA enzyme I mutant consists of the sequence of SEQ ID NO: 2.In some embodiments, the DNase I mutant comprises one or more mutations selected from the group consisting of: H44C, H44N, L45C, V48C, G49C, L52C, D53C, D53R, D53K, D53Y, D53A, N56C, D58S, D58T, Y65A, Y65E, Y65R, Y65C, V66N, V67E, V67K, V67C, E69R, E69C, A114C, A114R, H44 N:T46S, D53R:Y65A, D53R:E69R, H44A:D53R:Y65A, H44A:Y65A:E69R, H64N:V66S, H64N:V66T, Y65N:V67S, Y65N:V67T, V66N:S68T, V67N:E69S, V67N:E69T, S68N:P70S, S68N:P70T, S94N:Y96S, S94N:Y96T and any combination thereof. In some embodiments, the enzyme having DNase activity is a fusion protein comprising (i) DNase or a fragment thereof connected to (ii) albumin or Fc or a fragment thereof. In some embodiments, the sequence encoding the enzyme having DNase activity comprises a sequence encoding a secretion signal sequence, wherein the secretion signal sequence mediates the effective secretion of the enzyme. In some embodiments, the secretion signal sequence is selected from the group consisting of: a DNase I secretion signal sequence, an IL2 secretion signal sequence, an albumin secretion signal sequence, a β-glucosidase secretion signal sequence, an alkaline protease secretion signal sequence, and a fibronectin secretion signal sequence. In some embodiments, the secretion signal sequence comprises the sequence MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6) or MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7). In some embodiments, the secretion signal sequence consists of the sequence MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6) or MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7). In some embodiments, the secretion signal sequence comprises a sequence having at least 80% or at least 85% or at least 90% or at least 95% sequence identity to the sequence of MRGMKLLGALLALAALLQGAVS (SEQ ID NO: 6) or a sequence having at least 85% or at least 90% or at least 95% sequence identity to the sequence of MYRMQLLSCIALSLALVTNS (SEQ ID NO: 7). In some embodiments, the secretion signal sequence consists of the sequence MRYTGLMGTLLTLVNLLQLAGT (SEQ ID NO: 8).In some embodiments, the secretion signal sequence comprises a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% sequence identity to the sequence of MRYTGLMGTLLTLVNLLQLAGT (SEQ ID NO: 8).

[0102] The administration of the DNA enzyme according to the method of the present invention can be carried out by any suitable approach, including systemic administration and direct administration to the disease site (e.g., administration to a primary tumor). Specific non-limiting examples of useful administration routes include intravenous (IV), subcutaneous (SC), intraperitoneal (IP), oral and intramuscular.

[0103] In the method for the present invention, useful DNA enzyme protein dosage depends on the type of other therapy, the clinical history of the patient and the response to DNA enzyme, and the judgment of the attending physician.The limiting examples of useful dosage range include from 0.005mg / kg / day to 100mg / kg / day, or from 10KU / kg / day to 200000KU / kg / day, preferably from 0.05mg / kg / day to 50mg / kg / day, or from 1000Kunitz unit (KU) / kg / day to 100000Kunitz unit (KU) / kg / day, more preferably from 1.5mg / kg / day to 50mg / kg / day, or from 3000KU / kg / day to 100000KU / kg / day, most preferably from 10mg / kg / day to 50mg / kg / day, or from 20000KU / kg / day to 100000KU / kg / day.

[0104] In some embodiments, the DNase protein is injected intravenously at 250 μg / kg / day. In some embodiments, the DNase protein is injected intravenously at 250 μg / kg / day for at least 14 days.

[0105] DNA enzyme compositions and preparations

[0106] In certain embodiments, the DNase protein, DNase encoding vector or DNase expressing cell is formulated into a pharmaceutical composition with a pharmaceutically acceptable carrier or excipient. In certain embodiments, such a composition further comprises a second immunomodulator.

[0107] The formulations used in the methods of the present invention can be conveniently presented in unit dosage form and can be prepared by methods known in the art. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the host being treated and the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be the amount of the compound that produces a therapeutic effect.

[0108] In general, the formulations are prepared with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0109] Pharmaceutical compositions suitable for parenteral administration may comprise one or more active ingredients ((i) DNase protein, DNase encoding vector or DNase expressing cell, and optionally (ii) another compound [e.g., a second immunomodulator or another anticancer compound]), in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions or sterile powders, which may be reconstituted into sterile injectable solutions or dispersions prior to use, and which may comprise antioxidants, buffers, bacteriostats, solutes or suspending agents or thickeners that make the preparation isotonic with the blood of the intended recipient. Examples of suitable aqueous and non-aqueous carriers that may be used for the pharmaceutical compositions of the present invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate). Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[0110] These compositions may also contain preservatives, wetting agents, emulsifiers and dispersants. Preventing the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars, sodium chloride, etc. in the compositions. In addition, prolonged absorption of injectable pharmaceutical forms may be caused by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

[0111] Injectable depot forms can be prepared by forming a microcapsule matrix of one or more active ingredients in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of active ingredient to polymer and the properties of the specific polymer used, the rate of release of the active ingredient can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by encapsulating the active ingredient in a liposome or microemulsion compatible with body tissues.

[0112] Formulations for oral administration may be in the form of capsules, cachets, pills, tablets, powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid (e.g., as a mouthwash, as a composition to be swallowed, or as an enema), or as an oil-in-water or water-in-oil liquid emulsion, etc., each containing a predetermined amount of one or more active ingredients.

[0113] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), one or more active ingredients may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic ; (3) humectants such as glycerol; (4) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) solution retardants such as paraffin; (6) absorption accelerators such as quaternary ammonium compounds; (7) wetting agents such as, for example, cetyl alcohol and glyceryl monostearate; (8) absorbents such as kaolin and bentonite; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain a buffer. A similar type of solid composition may also be employed, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols as fillers in soft-filled and hard-filled gelatin capsules.

[0114] Suspensions, in addition to one or more active ingredients, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0115] In addition to one or more active ingredients, powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain conventional propellants, such as fluorochlorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0116] Cancer and other treatments

[0117] The methods of the present invention can be used for subjects with a variety of cancers. Non-limiting examples of relevant cancers include, for example, breast cancer, prostate cancer, multiple myeloma, transitional cell carcinoma, lung cancer (e.g., non-small cell lung cancer (NSCLC)), kidney cancer, thyroid cancer, leukemia (e.g., chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia), lymphoma (e.g., B cell lymphoma, T cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma), head and neck cancer, esophageal cancer, gastric cancer, colon cancer, intestinal cancer, colorectal cancer, rectal cancer, pancreatic cancer, liver cancer, bile duct cancer, gallbladder cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, bladder cancer, neuroblastoma, sarcoma, osteosarcoma, malignant melanoma, squamous cell carcinoma, bone cancer (including Primary bone cancer (e.g., osteosarcoma, chondrosarcoma, Ewing's sarcoma, fibrosarcoma, malignant fibrous histiocytoma, adamantoma, giant cell tumor, and chordoma) and secondary (metastatic) bone cancer), soft tissue sarcoma, basal cell carcinoma, angiosarcoma, hemangiosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, gastrointestinal cancer, mesothelioma, leiomyosarcoma, rhabdomyosarcoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia macroglobulinemia), papillary adenocarcinoma, cystadenocarcinoma, bronchogenic carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, epithelial carcinoma, glioma, glioblastoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, medullary carcinoma, thymoma, sarcoma, etc.

[0118] In some embodiments, in addition to administering a DNA enzyme and a second immunomodulator, the treatment methods of the present invention may also include administering additional anti-cancer agents and / or therapies, including but not limited to chemotherapeutic agents, radiation therapy, cell therapy (e.g., cells containing chimeric antigen receptors (CAR) or T cell receptors (TCR), NK cells, CD8 T cells, etc.), and any combination thereof.

[0119] In some embodiments of any of the methods of the invention, the subject is a human. Example

[0120] The present invention is also described and embodied by the following examples. However, the use of these and other examples anywhere in the specification is illustrative only and in no way limits the scope and meaning of the present invention or any exemplary term. Likewise, the present invention is not limited to any particular preferred embodiment described herein. In fact, after reading this specification, many modifications and variations of the present invention may be obvious to those skilled in the art, and such changes may be made without departing from the present invention in spirit or scope. Therefore, the present invention is limited only by the terms of the appended claims together with the full scope of equivalents granted by these claims.

[0121] Example 1. DNAzymes reduce the number of tumor-associated macrophages (TAMs) and tumor-infiltrating neutrophils (TINs) in tumor tissues.

[0122] Based on the conditions of the internal environment, circulating monocytes give rise to mature macrophages, and when they are recruited into the tumor microenvironment, they are transformed into tumor-associated macrophages (TAMs). TAMs not only lack the function of phagocytosing tumor cells, but also help these tumor cells escape being killed and help them spread to other tissues and organs. Tumor-infiltrating neutrophils (TINs) participate in the tumor microenvironment through cytokines and chemokines. TINs stimulate immunosuppression, tumor growth, angiogenesis, and metastasis through DNA instability or through the release of cytokines and / or chemokines.

[0123] BALB / c breast adenocarcinoma, MC38 colon carcinoma, Lewis lung carcinoma (LL2), and murine pancreatic adenocarcinoma (Panc2) cancer cell lines were used. 3×10e6 breast adenocarcinoma cells, 1×10e6 MC38 cells, 3×10e5 LL2 cells, or 2×10e5 Panc2 cells in 100 μl RPMI were administered subcutaneously into the mammary fat pad of 6- to 8-week-old syngeneic Balb / c or C57Bl / 6 female mice.

[0124] Six days after tumor implantation, animals were randomly assigned to groups (N=3) and treated daily by IV injection of 75 μg human recombinant DNase I (Kevelt AS; SEQ ID NO: 1) per mouse, with the control group receiving the same amount of PBS. To separate TAMs and TINs, tumors were extracted and treated with 12U / mL collagenase I (Sigma), 450U / mL collagenase IV (Sigma) and 50U / mL DNase I (Kevelt). Debris and dead cells were removed with a density gradient. To purify TAMs, F4 / 80 cells were additionally MACS-enriched (using anti-CD11b microbeads) (Sigma).

[0125] The amounts of TAM and TIN after treatment with DNase were Figure 1 A and Figure 1 Shown in B are % relative to control (taken as 100%). The data clearly demonstrate that daily IV injection of DNase I enzyme provided a statistically significant (p<0.05) reduction in TAM and TIN.

[0126] Example 2. Effects of different administration regimens of DNA enzymes on the abundance of TAMs and TINs in tumor tissues.

[0127] 1×10e5 Panc2 cells in 100 μl RPMI were injected subcutaneously into 6- to 8-week-old syngeneic C57Bl / 6 female mice.

[0128] Six days after tumor implantation, animals were randomly assigned to groups (N=3):

[0129] Group 1: untreated control;

[0130] Group 2: Human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 1 mg / kg daily for 7 days;

[0131] Group 3: human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) injected IV at a dose of 2 mg / kg daily for 14 days;

[0132] Group 4: human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) injected IV at a dose of 2 mg / kg daily for 7 days;

[0133] Group 5: human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) injected IV at a dose of 2 mg / kg daily for 2 days;

[0134] Group 6: human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) injected IV at a dose of 2 mg / kg for 2 days per week for 3 weeks;

[0135] Group 7: Human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg for 2 days in weeks 1 and 3 for 3 weeks.

[0136] To separate TAMs and TINs, tumors were extracted and treated with 12 U / mL collagenase I, 450 U / mL collagenase IV, and 50 U / mL DNase I. Debris and dead cells were removed using a density gradient. To purify TAMs, F4 / 80 cells were additionally MACS-enriched (using anti-CD11b microbeads).

[0137] The amounts of TAM and TIN are Figure 2 A and Figure 2 Shown in B.

[0138] Surprisingly, all used regimens of DNase I administration provided statistically significant (p<0.05) reductions in TAMs and TINs.

[0139] Example 3. Effects of different times of initiation of DNAse therapy on the abundance of TAMs and TINs in tumor tissues.

[0140] 3 x 10e6 mammary adenocarcinoma cells in 100 μl RPMI were injected into 6- to 8-week-old syngeneic Balb / c female mice.

[0141] Animals were randomly assigned to groups (N=3):

[0142] Group 1: untreated control;

[0143] Group 2: Human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg every 3 days starting from day 2 after tumor implantation for a total of 21 days;

[0144] Group 3: Starting from day 6 after tumor implantation, human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0145] Group 4: Starting from day 10 after tumor implantation, human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0146] Group 5: Starting from day 14 after tumor implantation, human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0147] Group 6: Human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV every 3 days at a dose of 2 mg / kg, starting from day 18 after tumor implantation, for a total of 21 days.

[0148] To separate TAMs and TINs, tumors were extracted and treated with 12 U / mL collagenase I, 450 U / mL collagenase IV, and 50 U / mL DNase I. Debris and dead cells were removed using a density gradient. To purify TAMs, F4 / 80 cells were additionally MACS-enriched (using anti-CD11b microbeads).

[0149] The amounts of TAM and TIN are Figure 3 A and Figure 3 Shown in B.

[0150] Unexpectedly, administration of DNase I provided a statistically significant (p<0.05) reduction in TAMs and TINs even at late stages of tumor development.

[0151] Example 4. Effect of the combination of DNAse therapy and immune checkpoint inhibitors on the abundance of TAMs and TINs in tumor tissues.

[0152] 1×10e6 CT26 cells or MC38 cells in 100 μl RPMI were injected into 6- to 8-week-old female mice.

[0153] Treatment started on day 3 or day 10 after tumor implantation.

[0154] Animals were randomly assigned to groups (N=3):

[0155] Group 1: untreated control;

[0156] Group 2: Human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV every 3 days at a dose of 2 mg / kg starting from day 3 after tumor implantation;

[0157] Group 3: Starting from day 10 after tumor implantation, human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0158] Group 4: Starting from the 3rd day after tumor implantation, anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0159] Group 5: Starting from day 10 after tumor implantation, anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0160] Group 6: Starting from day 3 after tumor implantation, IV injection of anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) every 3 days + starting from day 3 after tumor implantation, IV injection of human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0161] Group 7: Starting from day 10 after tumor implantation, IV injection of anti-mouse CTLA4 antibody (BEO146, InVivoMAb, 200 μg / dose) every 3 days + starting from day 10 after tumor implantation, IV injection of human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0162] Group 8: Starting from the 3rd day after tumor implantation, anti-mouse CTLA4 antibody (BEO146, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0163] Group 9: Starting from day 10 after tumor implantation, anti-mouse CTLA4 antibody (BEO146, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0164] Group 10: Starting from day 3 after tumor implantation, IV injection of anti-mouse CTLA4 antibody (BEO146, InVivoMAb, 200 μg / dose) every 3 days + starting from day 3 after tumor implantation, IV injection of human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0165] Group 11: Starting from day 10 after tumor implantation, IV injection of anti-mouse CTLA4 antibody (BEO146, InVivoMAb, 200 μg / dose) every 3 days + starting from day 10 after tumor implantation, IV injection of human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0166] Group 12: Starting from the 3rd day after tumor implantation, anti-mouse OX-40 antibody (BE0031, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0167] Group 13: Starting from day 3 after tumor implantation, IV injection of anti-mouse OX-40 antibody (BE0031, InVivoMAb, 200 μg / dose) every 3 days + starting from day 3 after tumor implantation, IV injection of human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days for a total of 21 days;

[0168] Group 14: Starting from day 10 after tumor implantation, anti-mouse OX-40 antibody (BE0031, InVivoMAb, 200 μg / dose) was injected IV every 3 days for a total of 21 days;

[0169] Group 15: Anti-mouse OX-40 antibody (BE0031, InVivoMAb, 200 μg / dose) was injected IV every 3 days starting from day 10 after tumor implantation + human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) was injected IV every 3 days at a dose of 2 mg / kg starting from day 10 after tumor implantation for a total of 21 days.

[0170] TAMs were extracted from tumors as described previously. The amounts of TAMs and TINs were Figure 4 Shown in.

[0171] When used alone, checkpoint inhibitors statistically significantly reduced TAM abundance at tumor sites early in tumor progression, but were unable to do so once they were used at a more advanced stage of the disease (when given to animals after 10 days post-tumor implantation). Unexpectedly, immune checkpoint inhibitors continued to significantly (p<0.05) reduce TAMs when combined with DNase I.

[0172] Example 5. Effects of different types of DNA enzymes on the tumor microbiome.

[0173] Fusobacterium nucleatum (F.nucleatum) is an oral anaerobic bacterium that has recently been found to be prevalent in human colorectal cancer (CRC), breast cancer, and some other cancers, where it is associated with poor treatment outcomes and a tumor immunosuppressive environment. Inoculation with Fusobacterium nucleatum leads to tumor colonization, inhibits the accumulation of tumor-infiltrating T cells, and promotes tumor growth and metastatic progression. See, e.g., Kostic et al., Cell hostµbe, 2013, 14(2): 207-15; Van der Merwe et al., Immunology Letters, 2021, 232: 60-66.

[0174] Fusobacterium nucleatum (ATCC 25586) was cultured on Columbia agar supplemented with 5% sheep red blood cells at 37°C in 5% CO 2Breast cancer cell line AT3 (ATCC) was injected into the mammary fat pad of 6- to 8-week-old C57BL / 6 animals. Animals were randomly assigned to groups (N=3). The study was terminated on Day 24.

[0175] Group 1: untreated control;

[0176] Group 2: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726;

[0177] Group 3: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and animals were treated with metronidazole 10 mg / kg on days 2, 3, 4, 5, 6, and 7 after bacterial injection;

[0178] Group 4: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with human recombinant DNase I enzyme (Kevelt AS; SEQ ID NO: 1) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection;

[0179] Group 5: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with mut DNase I enzyme (Kevelt AS) (SEQ ID NO: 2) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection;

[0180] Group 6: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and treated with DNase-1-like 3 (Human Microbiology Institute, NY, USA) (SEQ ID NO: 3) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection;

[0181] Group 7: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with DNase-1-like 3 (SEQ ID NO: 3) at a given dose of 2 mg / kg 1 day and 4 days after bacterial injection;

[0182] Group 8: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and treated with DNase-1-like 2 (Human Microbiology Institute, NY, USA) (SEQ ID NO: 4) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection;

[0183] Group 9: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with DNase-1-like 1 (Kevelt AS) (SEQ ID NO: 5) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection.

[0184] Tumor volumes were measured with calipers and estimated using the ellipsoid formula. Data are available at Figure 5 The data clearly demonstrate that IV injection of different types of human recombinant DNase I enzymes provided statistically significant (p<0.05) protection against F. nucleatum-triggered tumor growth and prevented the pro-tumorigenic effects of F. nucleatum.

[0185] On the day of study termination, the presence of Fusobacterium nucleatum in tumor tissue was confirmed by plating tumor homogenates on nutrient medium and incubating at 37°C under anaerobic conditions for 48 hours. Additional PCR analysis was performed on tumor tissue and colonies that produced growth. The data are shown in Table 1.

[0186] Table 1. Quantification of Fusobacterium nucleatum in tumor tissues

[0187]

[0188] *The amount of F. nucleatum was normalized to the percentage in each experiment compared to the mean F. nucleatum in Group 2 (positive control set to 100%). Data are shown as ± SD.

[0189] The data clearly show that DNase does not alter the amount of Fusobacterium nucleatum at the tumor site and has no antibacterial activity in these environments. Unexpectedly, DNase I significantly inhibited the tumorigenic effects of Fusobacterium nucleatum. In this study, the DNase administration regimen had little effect on the results, and multiple types of DNase were equally effective.

[0190] Example 6. Effect of the tumor microbiome on the anti-tumor activity of immune checkpoint inhibitors.

[0191] Fusobacterium nucleatum ATCC 25586 was cultured on Columbia agar supplemented with 5% sheep red blood cells at 37°C in 5% CO 2 AT3 breast cancer cell line was injected into the mammary fat pad of 6- to 8-week-old C57BL / 6 mice weighing 18-22 g. Animals were randomly assigned to groups (N=5). The study was terminated on day 21.

[0192] Group 1: untreated control;

[0193] Group 2: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726;

[0194] Group 3: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and animals were treated with metronidazole 10 mg / kg (Sigma) 2, 3, 4, 5, 6, and 7 days after bacterial injection;

[0195] Group 4: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with human recombinant DNase I (Kevelt AS; SEQ ID NO: 1) at a given dose of 2 mg / kg every 3 days starting from day 1 after bacterial injection;

[0196] Group 5: injection of anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) every 2 days;

[0197] Group 6: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726 and treated with anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) every 2 days starting from bacterial injection;

[0198] Group 7: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and treated with human recombinant DNase I (Kevelt AS; SEQ ID NO: 1) at a dose of 2 mg / kg every 3 days starting from the first day after bacterial injection; and anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) was administered every 2 days starting from bacterial injection;

[0199] Group 8: injected with 7.5×10e7 Fusobacterium nucleatum ATCC 23726, and treated with human recombinant DNase I (Kevelt AS; SEQ ID NO: 1) at a given dose of 2 mg / kg every 3 days starting from the first day after bacterial injection; and anti-mouse CTLA4 antibody (BEO164, InVivoMAb, 200 μg / dose) was administered every 2 days starting from bacterial injection.

[0200] Tumor volumes were measured with calipers and estimated using the ellipsoid formula. Data are available at Figure 6 Shown in.

[0201] On the last day, the presence of Fusobacterium nucleatum in tumor tissue was confirmed by plating tumor homogenate on nutrient medium and incubating at 37°C under anaerobic conditions for 48 hours. Additional PCR analysis was performed on tumor tissue and colonies that produced growth. The data are shown in Table 2.

[0202] Table 2. Quantification of Fusobacterium nucleatum in tumor tissues

[0203]

[0204]

[0205] *The amount of F. nucleatum was normalized to the percentage in each experiment compared to the mean F. nucleatum in Group 2 (positive control set to 100%). Data are shown as ± SD.

[0206] The data clearly showed that Fusobacterium nucleatum significantly inhibited the anti-cancer activity of the immune checkpoint inhibitor anti-CTLA4 antibody. Unexpectedly, treatment with a combination of checkpoint inhibitors and DNase I enzymes improved the pro-cancer and anti-immune tumor activities of Fusobacterium nucleatum (p<0.05) without affecting the viability of the microorganism.

[0207] Another unexpected finding of this study was that F. nucleatum increased the toxic effects of anti-CTLA4 antibody checkpoint inhibitor treatment, and treatment with the combination of this checkpoint inhibitor and DNase I improved F. nucleatum-induced toxicity as well as anti-CTLA4 antibody-induced toxicity. Figure 7 As shown in , administration of anti-CTLA4 antibody (at 3 mg / kg) or F. nucleatum (7.5×10e7) alone stopped weight gain in treated animals, the combination of anti-CTLA4 antibody and F. nucleatum resulted in severe weight loss, and DNase I treatment (at 2 mg / kg) prevented anti-CTLA4 antibody and / or F. nucleatum-induced toxicity and resulted in weight gain.

[0208] sequence

[0209] SEQ ID NO: 1—Mature wild-type (WT) human DNase I (without secretion signal sequence; Genbank accession number 4AWN_A):

[0210]

[0211] SEQ ID NO:2—Mature human DNase I mutant (without secretion signal sequence); mutated residues compared to SEQ ID NO:1 are indicated in bold and underlined:

[0212]

[0213] SEQ ID NO:3-Human DNA enzyme-1-like 3

[0214]

[0215] SEQ ID NO:4 - Human DNA enzyme-1-like 2

[0216]

[0217] SEQ ID NO:5 - Human DNAse - l - like 1

[0218]

[0219] References:

[0220] Song, L. et al., “NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies” Front. Cell. Neurosci., 2017, Vol. 11, No. 63.

[0221] Fleischhacker M. et al., “Circulating nucleic acids(CNAs) and cancer: a survey” Biochim Biophys Acta, 2007, 1775(1): 181 - 232.

[0222] Demers, M. at al., “Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer - associated thrombosis” PNAS, 2012, 109(32): 13076 - 13081.

[0223] García - Olmo D.C. and García - Olmo, D. “Biological role of cell - free nucleic acids in cancer: the theory of genomestasis” Crit Rev Oncolog, 2013, 18:153 - 161.

[0224] Sawyers 2008C.L., “The cancer biomarker problem” Nature, 2008, 452(7187): 548 - 552.

[0225] Butt AN. et al. Overview of circulating nucleic acids in plasma / serum Ann. NY. Acad. Sci., 2008, 1137: 236 - 242.

[0226] Schwarzenbach H.et al.,“Detection and monitoring of cell-free DNA inblood of patients with colorectal cancer”Ann.N.Y.Acad.Sci.,2008,1137:190-196.

[0227] Zenaro E,et al.,Neutrophils promote Alzheimer’s disease-likepathology and cognitive decline via LFA-1 integrin.Nat Rev Nephrol.,2015,Author manuscript;available in PMC 2017Jul 14.

[0228] Fushi,W.et al.,“Extracellular DNA in Pancreatic Cancer Promotes CellInvasion and Metastasis”Cancer Res.,2013,73:4256-4266.

[0229] Tohme,S.et al.,“Neutrophil Extracellular Traps Promote theDevelopment and Progression of Liver Metastases after Surgical Stress”CancerRes.,2016,76(6):1367-1380.

[0230] Patutina,O.et al.,Inhibition of metastasis development by dailyadministration of ultralow doses of RNase A and DNase I.Biochimie.,2011,93(4):689-96.

[0231] Dan Li, DNase I Treatment Reduces GVHD in Mice. Biology of Blood and Marrow Transplantation, Volume 21, Issue 2, Page S339.

[0232] Darvin, P.et al., "Immune checkpoint inhibitors: recent progress and potential biomarkers" Experimental & molecular medicine, 2018, 50(12): 1-1.

[0233] ***

[0234] The scope of the present invention is not limited by the specific embodiments described herein. In fact, various modifications of the present invention, except those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are expected to fall within the scope of the appended claims.

[0235] All patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated by reference in their entirety, as if physically present in this specification.

Claims

1. A method for immunomodulating an immunosuppressive tumor cell microenvironment in a subject having cancer, comprising administering to the subject an effective amount of a deoxyribonuclease (DNase).

2. The method according to claim 1, wherein the immunomodulation comprises an increase in the killing of tumor cells by cytotoxic CD8 T cells and / or NK cells and / or CAR-T cells in the immunosuppressive tumor cell microenvironment.

3. A method for modulating a tumor-associated microbiome in a subject having cancer, comprising administering to the subject an effective amount of a deoxyribonuclease (DNase).

4. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a deoxyribonuclease (DNase) and a second immunomodulator.

5. The method according to any one of claims 1-4, wherein the administration of the DNase effectively reduces the number and / or activity of tumor-associated macrophages (TAMs) and / or tumor-infiltrating neutrophils (TINs) in the immunosuppressive tumor cell microenvironment.

6. The method of claim 4 or claim 5, wherein the second immunomodulator is an immune checkpoint regulator.

7. The method of claim 6, wherein the immune checkpoint regulator is a regulator of an immune checkpoint molecule selected from the group consisting of PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligands.

8. The method of claim 6 or claim 7, wherein the immune checkpoint regulator is an immune checkpoint inhibitor.

9. The method of claim 8, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1 or PD-L2.

10. The method of claim 8, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA or SIGLEC7.

11. The method of claim 8, wherein the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cemiplizumab, and any combination thereof.

12. The method of claim 11, wherein the immune checkpoint inhibitor is pembrolizumab.

13. according to the method described in any one of claims 1-12, wherein the DNA enzyme is selected from human DNA enzyme I, human DNA enzyme-1-sample 3 (D1L3), human DNA enzyme-1-sample 2 (D1L2), human DNA enzyme-1-sample 1 (D1L1), DNA enzyme X, DNA enzyme γ, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ and caspase-activated DNA enzyme (CAD).

14. The method of any one of claims 1-12, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to a human DNase I enzyme.

15. The method of claim 14, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

1.

16. The method of any one of claims 1-12, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of the DNA enzyme 1-like 3 (D1L3) enzyme.

17. The method of claim 16, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:

3.

18. The method according to any one of claims 1-12, wherein the DNA enzyme comprises the amino acid sequence SEQ ID NO:

2.

19. The method according to any one of claims 1-18, wherein the DNase is administered as DNase protein.

20. The method of claim 19, wherein the DNase protein is administered intravenously for at least 2 days.

21. The method of claim 20, wherein the DNase protein is administered intravenously for at least 7 days.

22. The method of claim 21, wherein the DNase protein is administered intravenously for at least 14 days.

23. The method of claim 22, wherein the DNase protein is administered intravenously for at least 16 days.

24. The method of claim 19, wherein the DNase protein is administered intravenously for 1 to 2 days every 2 weeks, 3 weeks, or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years.

25. The method of claim 19, wherein the DNase protein is administered intravenously for 2 to 5 days every 2 weeks, 3 weeks, or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years.

26. The method of claim 19, wherein the DNase protein is administered intravenously for 7 to 14 days every 2 weeks, 3 weeks, or 4 weeks, wherein the total length of treatment is 2 weeks to 50 years.

27. The method of claim 19, comprising administering the DNase protein to the subject 120 hours to 1 hour prior to administering the second immunomodulator.

28. The method of claim 19, comprising administering the DNase protein to the subject 30 minutes to 2 hours after administering the second immunomodulator.

29. The method of claim 19, comprising administering the DNase protein to the subject 2 hours to 360 hours after administration of the second immunomodulator.

30. The method of any one of claims 19-29, wherein the DNase protein is administered at 125 μg / kg / day - 250 μg / kg / day.

31. The method of any one of claims 1-18, wherein the DNase is encoded by a gene therapy vector.

32. The method of claim 31 , wherein the gene therapy vector is administered to the subject.

33. A method according to claim 31 or claim 32, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding the DNA enzyme.

34. The method of claim 32, wherein the promoter is selected from the group consisting of a liver-specific promoter, a nervous system-specific promoter, an intestine-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestine-specific tandem promoter.

35. The method of claim 33, wherein the promoter is specific to a tumor tissue of origin or a metastasis target tissue.

36. The method of any one of claims 33-35, wherein the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1 and Anc 80.

37. The method of any one of claims 1-18, wherein the DNA enzyme is expressed by a cell comprising a chimeric antigen receptor (CAR) or a T cell receptor (TCR), and wherein the cell is administered to the subject.

38. The method of claim 37, wherein the CAR-expressing cells or TCR-expressing cells are administered directly to the tumor site.

39. The method of claim 37 or claim 38, wherein the CAR-expressing cells or TCR-expressing cells are single-target or multi-target.

40. The method of any one of claims 37-39, wherein the CAR comprises an antigen binding domain capable of specifically binding to one or more tumor antigens.

41. The method of any one of claims 4-40, wherein administration of the DNase is effective to reduce the severity of one or more immune-related adverse events associated with use of the second immunomodulator.

42. The method of claim 41, wherein the immune-related adverse event is cytokine release syndrome (CRS).

43. The method of claim 41, wherein the one or more immune-related adverse events are selected from uveitis, syndrome, conjunctivitis, blepharitis, episcleritis, scleritis, retinitis, pneumonia, pleurisy, sarcoid granulomatosis, hepatitis, pancreatitis, autoimmune diabetes, interstitial nephritis, glomerulonephritis, acute kidney injury (AKI), rash, pruritus, vitiligo, DRESS, psoriasis, Stevens-Johnson syndrome, arthralgia, arthritis, myositis, dermatomyositis, anemia, neutropenia, thrombocytopenia, thrombotic microangiopathy, acquired hemophilia, vasculitis, colitis, enteritis, gastritis, myocarditis, pericarditis, hypophysitis, thyroiditis, adrenalitis, encephalitis, meningitis, polyneuropathy, Guillain-Barré syndrome, and subacute inflammatory neuropathy.

44. The method of any one of claims 1-43, wherein administration of the DNase results in a change in the content and / or activity of a tumor microbiome in the subject.

45. The method of claim 44, wherein the tumor microbiome comprises one or more bacterial taxa selected from the group consisting of Acidobacteria, Actinobacteria, Bacteroidetes, Chlamydiae, Chrysiogenetes, Cyanobacteria, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes, Lentisphaerae, Proteobacteria, Spirochaetes, Synergistetes, Tenericutes, and Verrucomicrobia.

46. ​​according to the method described in any one of claims 1-45, wherein said DNA enzyme is administered before, together with or after cell therapy.

47. The method of claim 46, wherein the cell therapy comprises administering (i) cells comprising a chimeric antigen receptor (CAR) or a T cell receptor (TCR), and / or (ii) NK cells, and / or (iii) CD8 T cells.

48. The method of any one of claims 1-47, wherein the subject is a human.

49. A pharmaceutical composition comprising deoxyribonuclease (DNase), a second immunomodulator and a pharmaceutically acceptable carrier or excipient.

50. The pharmaceutical composition of claim 49, wherein the second immunomodulator is an immune checkpoint regulator.

51. A pharmaceutical composition according to claim 50, wherein the immune checkpoint regulator is a regulator of the following immune checkpoint molecules selected from: PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligands.

52. A pharmaceutical composition according to claim 50 or claim 51, wherein the immune checkpoint regulator is an immune checkpoint inhibitor.

53. The pharmaceutical composition of claim 52, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1 or PD-L2.

54. A pharmaceutical composition according to claim 52, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA or SIGLEC7.

55. The pharmaceutical composition of claim 52, wherein the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cemiplizumab, and any combination thereof.

56. The pharmaceutical composition of claim 55, wherein the immune checkpoint inhibitor is pembrolizumab.

57. according to the pharmaceutical composition described in any one of claim 49-56, wherein the DNA enzyme is selected from human DNA enzyme I, human DNA enzyme-1-sample 3 (D1L3), human DNA enzyme-1-sample 2 (D1L2), human DNA enzyme-1-sample 1 (D1L1), DNA enzyme X, DNA enzyme γ, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ and caspase-activated DNA enzyme (CAD).

58. The pharmaceutical composition of any one of claims 49-56, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to a human DNase I enzyme.

59. The pharmaceutical composition of claim 58, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

1.

60. A pharmaceutical composition according to any one of claims 49-56, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of the DNA enzyme 1-like 3 (D1L3) enzyme.

61. The pharmaceutical composition of claim 60, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:

3.

62. A pharmaceutical composition according to any one of claims 49-56, wherein the DNA enzyme comprises the amino acid sequence SEQ ID NO:

2.

63. according to the pharmaceutical composition described in any one in claim 49-62, wherein said DNA enzyme is present in said composition in the form of DNA enzyme protein.

64. A pharmaceutical composition according to any one of claims 49-62, wherein the DNA enzyme is present in the composition in the form of a gene therapy vector encoding the DNA enzyme.

65. A pharmaceutical composition according to claim 64, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding the DNA enzyme.

66. The pharmaceutical composition of claim 65, wherein the promoter is selected from a liver-specific promoter, a nervous system-specific promoter, an intestine-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestine-specific tandem promoter.

67. The pharmaceutical composition of claim 65, wherein the promoter is specific to a tumor-originating tissue or a metastasis target tissue.

68. A pharmaceutical composition according to any one of claims 65-67, wherein the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1 and Anc 80.

69. A pharmaceutical composition according to any one of claims 49-62, wherein the DNA enzyme is present in the composition in the form of a cell expressing the DNA enzyme and also comprising a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

70. A pharmaceutical composition according to claim 69, wherein the CAR-expressing cells or TCR-expressing cells are single-target or multi-target.

71. A pharmaceutical composition according to claim 69 or claim 70, wherein the CAR comprises an antigen binding domain capable of specifically binding to one or more tumor antigens.

72. A pharmaceutical dosage form comprising deoxyribonuclease (DNase) and a second immunomodulatory agent.

73. The pharmaceutical dosage form of claim 72, wherein the second immunomodulator is an immune checkpoint regulator.

74. The pharmaceutical dosage form of claim 73, wherein the immune checkpoint regulator is a regulator of an immune checkpoint molecule selected from the group consisting of PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligands.

75. The pharmaceutical dosage form of claim 73 or claim 74, wherein the immune checkpoint modulator is an immune checkpoint inhibitor.

76. The pharmaceutical dosage form of claim 75, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1, or PD-L2.

77. A pharmaceutical dosage form according to claim 75, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA or SIGLEC7.

78. The pharmaceutical dosage form of claim 75, wherein the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cemiplizumab, and any combination thereof.

79. The pharmaceutical dosage form of claim 78, wherein the immune checkpoint inhibitor is pembrolizumab.

80. The pharmaceutical dosage form of any one of claims 72-79, wherein the DNase is selected from human DNase I, human DNase-1-like 3 (D1L3), human DNase-1-like 2 (D1L2), human DNase-1-like 1 (D1L1), DNase X, DNase γ, DNase II, DNase IIα, DNase IIβ, and caspase-activated DNase (CAD).

81. The pharmaceutical dosage form of any one of claims 72-79, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to a human DNase I enzyme.

82. The pharmaceutical dosage form of claim 81, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

1.

83. A pharmaceutical dosage form according to any one of claims 72-79, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of the DNase 1-like 3 (D1L3) enzyme.

84. The pharmaceutical dosage form of claim 83, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:

3.

85. The pharmaceutical dosage form according to any one of claims 72-79, wherein the DNA enzyme comprises the amino acid sequence SEQ ID NO:

2.

86. A pharmaceutical dosage form according to any one of claims 72-85, wherein the DNase is present in the dosage form in the form of DNase protein.

87. A pharmaceutical dosage form according to any one of claims 72-85, wherein the DNA enzyme is present in the dosage form in the form of a gene therapy vector encoding the DNA enzyme.

88. A pharmaceutical dosage form according to claim 87, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding the DNase.

89. The pharmaceutical dosage form according to claim 88, wherein the promoter is selected from the group consisting of a liver-specific promoter, a nervous system-specific promoter, an intestine-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestine-specific tandem promoter.

90. The pharmaceutical dosage form of claim 88, wherein the promoter is specific for a tumor tissue of origin or a metastasis target tissue.

91. The pharmaceutical dosage form of any one of claims 88-90, wherein the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1, and Anc 80.

92. A pharmaceutical dosage form according to any one of claims 72-85, wherein the DNA enzyme is present in the dosage form in the form of a cell that expresses the DNA enzyme and also comprises a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

93. The drug dosage form of claim 92, wherein the CAR-expressing cells or TCR-expressing cells are single-target or multi-target.

94. A pharmaceutical dosage form according to claim 92 or claim 93, wherein the CAR comprises an antigen binding domain capable of specifically binding to one or more tumor antigens.

95. A kit comprising deoxyribonuclease (DNase), a second immunomodulatory agent, and optionally instructions for use.

96. The kit of claim 95, wherein the second immunomodulator is an immune checkpoint regulator.

97. A kit according to claim 96, wherein the immune checkpoint regulator is a regulator of the following immune checkpoint molecules: PD-1, CD28, CTLA-4, CD137, CD40, CD134 (OX-40), ICOS, KIR, LAGS, CD27, TIM-3, BTLA, GITR, TCR, 4-1BB, TIGIT, CD96, CD226, KIR2DL, VISTA, HLLA2, TLIA, DNAM-1, CEACAM1, CD155, IDO, TGF-β, IL-10, IL-2, IL-15, CSF-1, IL-6, adenosine A2A receptor (A2AR) and its ligands.

98. The kit of claim 96 or claim 97, wherein the immune checkpoint regulator is an immune checkpoint inhibitor.

99. The kit of claim 98, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, OX-40, PD-L1 or PD-L2.

100. The kit of claim 98, wherein the immune checkpoint inhibitor is an antibody that specifically binds to CTLA-4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG 3, NOX2, TIM-3, VISTA or SIGLEC7.

101. The kit of claim 98, wherein the immune checkpoint inhibitor is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, MEDI0680, atezolizumab, avelumab, durvalumab, cemiplizumab, and any combination thereof.

102. The kit of claim 101, wherein the immune checkpoint inhibitor is pembrolizumab.

103. A test kit according to any one of claims 95-102, wherein the DNA enzyme is selected from human DNA enzyme I, human DNA enzyme-1-like 3 (D1L3), human DNA enzyme-1-like 2 (D1L2), human DNA enzyme-1-like 1 (D1L1), DNA enzyme X, DNA enzyme γ, DNA enzyme II, DNA enzyme IIα, DNA enzyme IIβ and caspase-activated DNA enzyme (CAD).

104. The kit of any one of claims 95-102, wherein the DNase comprises an amino acid sequence having at least 90% sequence identity to a human DNase I enzyme.

105. The kit of claim 104, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

1.

106. A kit according to any one of claims 95-102, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of the DNA enzyme 1-like 3 (D1L3) enzyme.

107. The kit of claim 106, wherein the DNA enzyme comprises an amino acid sequence having at least 90% sequence identity with amino acids 21 to 305 of SEQ ID NO:

3.

108. A kit according to any one of claims 95-102, wherein the DNA enzyme comprises the amino acid sequence SEQ ID NO:

2.

109. according to any one of claims 95-108 test kit, wherein the DNA enzyme is present in the test kit in the form of DNA enzyme protein.

110. A kit according to any one of claims 95-108, wherein the DNA enzyme is present in the kit in the form of a gene therapy vector encoding the DNA enzyme.

111. A kit according to claim 110, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding the DNA enzyme.

112. The kit of claim 111, wherein the promoter is selected from the group consisting of a liver-specific promoter, a nervous system-specific promoter, an intestine-specific promoter, a liver-specific / nervous system-specific tandem promoter, and a liver-specific / intestine-specific tandem promoter.

113. The kit of claim 111, wherein the promoter is specific for a tumor-originating tissue or a metastasis target tissue.

114. The kit of any one of claims 111-113, wherein the AAV is selected from serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVLK03, AAVLK06, AAVLK12, AAV-KP1, AAV-F, AAVDJ, AAVhu37, AAVrh64R1 and Anc 80.

115. A kit according to any one of claims 95-108, wherein the DNA enzyme is present in the kit in the form of a cell that expresses the DNA enzyme and also comprises a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

116. The kit of claim 115, wherein the CAR-expressing cells or TCR-expressing cells are single-target or multi-target.

117. A kit according to claim 115 or claim 116, wherein the CAR comprises an antigen binding domain capable of specifically binding to one or more tumor antigens.

Citation Information

Patent Citations

  • Method for treating systemic DNA mutation disease

    US20170056482A1

  • Method to improve safety and efficacy of Anti-cancer therapy

    US20170100463A1

  • Method for treating oncological diseases

    US7612032B2

Cited By

  • Application of Siglec7 in promoting cell generation and / or exosome release

    CN119506221A